
Argenica’s US stroke trial stalls as FDA demands rat brain study
Key points
- The US FDA has kept its clinical hold on Argenica’s planned US trial of stroke drug xaranetide, and wants an extra study in rats first.
- The regulator also lowered the permitted dose exposure below the levels in Argenica’s planned trial, a decision the company disputes.
- Argenica plans to request a Type A meeting with the FDA while continuing regulatory submissions in other countries.
Argenica Therapeutics (ASX:AGN) says the US Food and Drug Administration (FDA) has kept a clinical hold on its US trial plans for stroke drug xaranetide, and has asked for an additional rat study before any US patients can be dosed.
The Perth biotech submitted its complete response to the hold on 23 September 2026, and said the FDA’s decision arrived more than four weeks after the regulator’s mandatory 30-day deadline.
The FDA wants a lab-standard (GLP) study testing whether xaranetide causes Olney lesions in rats, a type of brain damage seen in rats given some drugs in this class, which Argenica said has not been shown to exist in humans.
The regulator also lowered the permitted drug exposure limit below the doses in Argenica’s proposed Phase 2b trial, a decision the company said it disagrees with, citing variability in the rat data the FDA relied on.
Argenica said it plans to request a Type A meeting with the FDA and will keep progressing regulatory submissions in other countries.
As at the time of reporting, the Argenica share price was $0.10.
The company said no microscopic brain damage has been found in animal studies of xaranetide to date, and that the FDA has offered to review the new study’s design in advance.
Xaranetide, also known as ARG-007, is designed to reduce brain tissue death after stroke, and Argenica said its Phase 2 trial showed a signal of benefit in patients with severe stroke.
Frequently asked questions
More from Australia
Echo IQ shares sink 42% as FDA upholds rejection
Australian Vintage names new CFO, starting January 2027
ASIC warns on QUFC Exchange, removes 20+ websites
WA Government commits $4m to life sciences hub
Count Financial wins Federal Court appeal in class action over advisor commissions
CurveBeam AI wins first China order for four scanners

